Country availability
Availability changes by country.
This table shows what we know by country. A blank cell would be misleading, so every cell either has a source or says it still needs research.
| Treatment / category | United States | Korea | China | Japan | EU / other |
|---|---|---|---|---|---|
| tunlametinib / HL-085 | Not assumed available China-specific approval source; no U.S. availability assumed. | Unknown / needs research Korean approval/reimbursement not mapped. needs research | Conditionally approved NMPA conditional marketing approval after anti-PD-1/PD-L1 failure. | Unknown / needs research PMDA status not mapped. needs research | Unknown / needs research EU regulatory status not mapped. needs research |
| nivolumab | Approved NCI/FDA drug context supports melanoma use; exact label depends on setting. | Available but context-dependent KCIC identifies nivolumab as a PD-1 checkpoint inhibitor; reimbursement map pending. | Unknown / needs research China label/reimbursement not mapped. needs research | Available but context-dependent PMDA nivolumab source identified; full label map pending. | Unknown / needs research EU label/reimbursement not mapped. needs research |
| pembrolizumab | Approved NCI drug page supports melanoma drug listing. | Available but context-dependent KCIC identifies pembrolizumab as a PD-1 checkpoint inhibitor; reimbursement map pending. | Unknown / needs research China label/reimbursement not mapped. needs research | Unknown / needs research PMDA label map pending. needs research | Unknown / needs research EU label/reimbursement not mapped. needs research |
| nivolumab + ipilimumab | Approved NCI drug page supports melanoma drug context. | Unknown / needs research Korean combination reimbursement map pending. needs research | Unknown / needs research China combination status pending. needs research | Unknown / needs research PMDA combination map pending. needs research | Unknown / needs research EU label/reimbursement not mapped. needs research |
| nivolumab + relatlimab | Approved FDA approval source identified for unresectable/metastatic melanoma context. | Unknown / needs research Korean status pending. needs research | Unknown / needs research China status pending. needs research | Unknown / needs research Japan status pending. needs research | Unknown / needs research EU status pending. needs research |
| lifileucel / TIL | Approved FDA accelerated approval source identified. | Unknown / needs research Korean TIL access/status pending. needs research | Unknown / needs research China TIL access/status pending. needs research | Unknown / needs research Japan TIL access/status pending. needs research | Unknown / needs research EU TIL access/status pending. needs research |
| dabrafenib + trametinib | Approved FDA adjuvant melanoma source identified for BRAF V600E/V600K context. | Unknown / needs research Korean BRAF/MEK access pending. needs research | Unknown / needs research China BRAF/MEK access pending. needs research | Unknown / needs research Japan BRAF/MEK access pending. needs research | Unknown / needs research EU BRAF/MEK access pending. needs research |
| encorafenib + binimetinib | Approved FDA approval source identified for unresectable/metastatic BRAF V600E/V600K melanoma. | Unknown / needs research Korean BRAF/MEK access pending. needs research | Unknown / needs research China BRAF/MEK access pending. needs research | Unknown / needs research Japan BRAF/MEK access pending. needs research | Unknown / needs research EU BRAF/MEK access pending. needs research |
| vemurafenib + cobimetinib | Available but context-dependent NCI drug page lists melanoma drug context; exact FDA page still to map. | Unknown / needs research Korean status pending. needs research | Unknown / needs research China status pending. needs research | Unknown / needs research Japan status pending. needs research | Unknown / needs research EU status pending. needs research |
| chemotherapy | Available but context-dependent NCI PDQ includes chemotherapy as a melanoma treatment category. | Available but context-dependent KCIC melanoma/treatment sources identified; specific regimen map pending. | Unknown / needs research China regimen context pending. needs research | Available but context-dependent Ganjoho melanoma source identified; specific regimen map pending. | Unknown / needs research EU regimen context pending. needs research |
| clinical trials | Available but context-dependent ClinicalTrials.gov/NCI can identify trial records; whether a study fits is never assumed. | Unknown / needs research Korean trial registry integration pending. needs research | Available but context-dependent China-specific trial work is partly mapped through NMPA/ClinicalTrials.gov leads. | Unknown / needs research Japanese registry integration pending. needs research | Available but context-dependent Some EU trial records appear in ClinicalTrials.gov; registry expansion pending. |